` LCTX (Lineage Cell Therapeutics Inc) vs Tel Aviv 355 Comparison - Alpha Spread

L
LCTX
vs
T
Tel Aviv 355

Over the past 12 months, LCTX has underperformed Tel Aviv 355, delivering a return of +0% compared to the Tel Aviv 355's +51% growth.

Stocks Performance
LCTX vs Tel Aviv 355

Loading
LCTX
Tel Aviv 355
Add Stock
www.alphaspread.com

Performance Gap
LCTX vs Tel Aviv 355

Loading
LCTX
Tel Aviv 355
Difference
www.alphaspread.com

Performance By Year
LCTX vs Tel Aviv 355

Loading
LCTX
Tel Aviv 355
Add Stock

Competitors Performance
Lineage Cell Therapeutics Inc vs Peers

Tel Aviv 355
LCTX
ABBV
CYTH
AMGN
GILD
Add Stock

Lineage Cell Therapeutics Inc
Glance View

Market Cap
190.9m ILS
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

LCTX Intrinsic Value
1 018.45 ILS
Undervaluation 63%
Intrinsic Value
Price
L
Back to Top